Skip to main content

Table 2 Prime-boost immunization trials against parasites

From: DNA vaccines: designing strategies against parasitic infections

Parasite

Antigen

Priming agent

Boosting agent

Response

Reference

Malaria

Circumsporozoite protein of P. berghei

Attenuated fowlpox virus or DNA

MVA

Potent CD8+ T cell responses were elicited in mice with FPV/MVA vaccination. Novel regimen was more protective against challenge than DNA-MVA immunizations.

[7]

 

P. falciparum surface protein (Pfs25)

DNA

Recombinant protein

Intramuscular injections in rhesus monkeys showed significant increase in transmission blocking antibodies.

[8]

 

Circumsporozoite protein of P. yoelii

DNA

Pox virus

Immunized neonatal mice showed 93% protection which was CD8+ T cell dependent.

[9]

 

P. falciparum erythrocyte binding protein

DNA

Recombinant protein

Higher antibody titers and the ability to reduce parasitemia without drug intervention in Aotus monkeys.

[10]

 

Circumsporozoite protein of P. falciparum

DNA

RTS, S/ASOZA

Malaria volunteers develop P. falciparum specific Abs and Th1 specific CD4+ and CD8+ T cells upon vaccination.

[11]

Leishmania

Leishmania infantum LACK

DNA

Recombinant vaccinia virus

60% protection, associated with cell mediated responses, was observed in dogs after challenge compared to controls.

[12]

 

p36/LACK

DNA

Recombinant vaccinia virus

Vaccination in mice resulted in 70% reduction in lesion size and 1000-fold reduction in parasite loads.

[13]

 

L. infantum acidic ribosomal protein PO (LiPO)

DNA

Recombinant protein

Boosting elicited stronger IgG2a titers but could not protect against challenge compared to DNA alone.

[14]

Schistosome

Cu/Zn cytosolic superoxide dismutase (SOD), signal peptide SOD and glutathione peroxidase (GP)

DNA

MVA

DNA vaccines were tested against S. masoni challenge in mice. Boosting with MVA for the same genes had no increased effect expect for mutated GP antigen were boosting lead to 85 % protection.

[15]